CPT-Pharmacometrics & Systems Pharmacology

Papers
(The H4-Index of CPT-Pharmacometrics & Systems Pharmacology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Issue Information45
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population43
Issue Information43
Evaluation of covariate effects in item response theory models35
Issue Information29
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension29
Pharmacometric and statistical considerations for dose optimization29
Issue Information29
Enhance Multistate Models With Clinically Meaningful Graphs28
Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation27
Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease27
Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates26
Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report26
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach25
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist24
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations24
A quantitative systems pharmacology approach to support mRNA vaccine development and optimization24
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval24
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models23
Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story23
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients22
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children21
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II21
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach21
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies21
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy21
0.10881590843201